GlassScriptPhysician profile
Jason Marten Smith
NPI 1699290296
$5,615.86
in general payments reported to CMS, 2019-2025
23 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.57 · 2022: $1,882 · 2023: $1,534 · 2024: $1,079 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,403 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,403.31 |
| Education | $233.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,434.45 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $857.82 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $668.35 | 2022-2025 | Ilumya |
| Genzyme Corporation | $472.98 | 2022-2025 | |
| Leo Pharma INC. | $460.44 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $322.51 | 2023-2025 | Tremfya |
| Amgen INC. | $191.50 | 2022 | |
| Nalu Medical, INC. | $181.78 | 2021-2023 | Nalu Neurostimulation System |
| Ucb, INC. | $177.01 | 2023-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $150.84 | 2023-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.28 | 2023-2025 | Spevigo, Cyltezo |
| Regeneron Healthcare Solutions, INC. | $121.63 | 2022-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $79.99 | 2022-2023 | Sotyktu |
| Boston Scientific Corporation | $56.84 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $49.95 | 2022-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $42.75 | 2022 | |
| Lilly USA, LLC | $35.79 | 2022-2024 | Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $33.36 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $24.59 | 2024 | Vtama |
| Nobelpharma America, LLC | $23.72 | 2025 | |
| Pierre Fabre Pharmaceuticals, INC. | $15.34 | 2023 | Hemangeol |
| Organon LLC | $2.94 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.